We’re pleased to announce a non-exclusive strategic partnership with The Compendium by Phenix Health Pty Ltd. Phenix Health Pty Ltd is a leader in digital health services, and through this partnership, Opyl will enhance the validation of clinical trials associated with cannabis products using its innovative AI platform, TrialKey. This collaboration will allow suppliers on The Compendium platform to access research-backed validation reports, assisting them in navigating the highly regulated medicinal cannabis market.
Key Highlights
- Non-Exclusive Partnership: Opyl and Phenix Health are partnering to validate the clinical trials associated with cannabis products using Opyl’s AI-powered TrialKey platform.
- Commercial Opportunity: With over 120 suppliers and 900+ products listed on Phenix Health’s Compendium platform, each validation report is priced at $5,000 AUD.
- Market Support: TrialKey will support suppliers by validating their clinical trials, helping them position these products to healthcare professionals effectively.
- Prioritisation of Suppliers: Suppliers using TrialKey reports will be prioritised on Phenix Health’s Compendium platform, providing them with a competitive edge.
About the Partnership
This strategic collaboration enables Phenix Health to utilise TrialKey’s advanced AI-driven simulation and predictive analytics within their platform. Comprehensive reports from TrialKey will offer valuable insights into trial variables, competitor assessments, patient recruitment strategies, and site selection recommendations.
The partnership enhances the ability of suppliers on the platform to navigate the complex medicinal cannabis market by leveraging data-backed validation for their clinical trials. This ensures that cannabis products featured on The Compendium meet regulatory and clinical standards, providing suppliers with an advantage in a competitive market.
Term and Termination Rights
This partnership will continue for 12 months, or until terminated with either party being able to terminate with 30 days’ written notice.
About The Compendium Platform
Phenix Health’s Compendium is the first clinician-only medicinal cannabis knowledge base designed to streamline the prescribing process and enhance clinical decision-making. Featuring 900+ products and 120+ suppliers, the platform provides clinicians with detailed, easily accessible product information, including constituent profiles, real-time stock updates, reported outcomes, validated research, and more.
By integrating TrialKey’s AI-driven validation, The Compendium adds an extra layer of credibility, helping clinicians and suppliers make data-driven decisions while enhancing the overall reliability of the platform.
Commercial Potential
While there is no direct financial exchange between Opyl and Phenix Health under this agreement, Opyl has the potential to generate significant revenue from the suppliers on The Compendium platform. Each validation report is priced at $5,000 AUD, offering suppliers a competitive advantage by validating their associated clinical trials using real-world data. As of this date, Opyl is not able to calculate the expected revenue from the suppliers on the platform but will update the market once this information is known to Opyl.
This partnership further solidifies Opyl’s leadership in AI-powered clinical trial validation, contributing to the growth of the medicinal cannabis sector. The agreement strengthens Opyl’s strategic positioning and its role in driving innovation across the cannabis market.
Leveraging Global Clinical Data for Local Success
Phenix Health will prioritise suppliers who have validated their clinical trials through TrialKey’s reports. With more than 120 suppliers and 900+ products on the Compendium platform, each report valued at $5,000, Opyl is positioned to tap into a substantial commercial opportunity. TrialKey’s reports provide a holistic view of the product’s trial history, drawing on global clinical trial data to ensure they meet Australia’s rigorous research standards.
The partnership addresses a significant challenge within the Australian medicinal cannabis market: the lack of local research, which has traditionally limited suppliers’ ability to market their products to healthcare professionals. Through TrialKey, Phenix Health suppliers gain access to robust global data, positioning them for greater success in the highly regulated market.
Executive Chairman, Saurabh Jain, commented:
“This partnership demonstrates the transformative potential of TrialKey in the cannabis industry. By delivering AI-powered validation reports for clinical trials, we provide suppliers with the crucial research they need to demonstrate the efficacy of their products, facilitating market entry and growth.”
Phenix Health CEO, Gillian Alexis, added:
“Our collaboration with Opyl enables us to offer suppliers the cutting-edge tools needed to navigate the complex regulatory environment in Australia. TrialKey’s data-driven validation reports are an essential resource for any supplier looking to build credibility and trust within the healthcare community.”
Bridging the Research Gap: AI-Powered Validation for Cannabis Suppliers
In Australia, where advertising cannabis products is restricted to healthcare professionals and must be grounded in scientific research, Opyl’s TrialKey offers a critical solution. By leveraging data from a global compendium of over 350,000 clinical trials, TrialKey enables suppliers on Phenix Health’s Compendium platform to validate the clinical trials associated with their cannabis products through comprehensive AI-generated reports. This validation supports suppliers in meeting the research demands of healthcare professionals, enhancing their credibility in the market.
For investor enquiries:
Bernice Averion
Head of Marketing and Communications
Email: bernice.averion@opyl.ai
